首页> 外文期刊>Global public health >Preferential adherence to antiretroviral therapy over tuberculosis treatment: A qualitative study of drug-resistant TB/HIV co-infected patients in South Africa
【24h】

Preferential adherence to antiretroviral therapy over tuberculosis treatment: A qualitative study of drug-resistant TB/HIV co-infected patients in South Africa

机译:与结核病治疗相比,坚持抗逆转录病毒疗法的依从性:南非耐药结核病/艾滋病毒合并感染患者的定性研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Adherence to antiretroviral therapy (ART) and second-line antituberculosis medications is essential to achieve successful outcomes among individuals co-infected with HIV and multi or extensively drug-resistant TB (M/XDR-TB). In 2012-2013, we designed a qualitative study to explore barriers to adherence in KwaZulu-Natal, South Africa. We conducted six focus groups comprising 23 adults receiving treatment for either MDR-TB (n = 2) or XDR-TB (n = 21); 17 were on concurrent ART. Participants expressed a preference for ART over M/XDR-TB treatment as a result of greater tolerability, lower pill burden and a commitment to ART. Treatment outcomes and the social morbidity associated with M/XDR-TB, characterised by public notification, stigma and social isolation, were perceived to be worse than with HIV. Poor communication, low patient involvement and provider supervision of treatment exacerbated participants' negative experiences with TB care. To improve adherence, it is critical that new regimens for drug-resistant TB be developed with better efficacy, lower pill burden and fewer adverse effects. For the first time, such improved regimens are on the horizon. In parallel and equally important is the implementation of a cohesive approach that promotes patient involvement, empowerment and treatment literacy for HIV and for TB.
机译:坚持抗逆转录病毒疗法(ART)和二线抗结核药物对于在感染HIV和多重耐药或广泛耐药结核病(M / XDR-TB)的个体中取得成功的结果至关重要。在2012-2013年,我们设计了定性研究,以探索南非夸祖鲁-纳塔尔省的遵守障碍。我们进行了六个焦点小组讨论,包括23名接受耐多药结核病(n = 2)或XDR-TB(n = 21)治疗的成年人。 17人同时进行ART。与会的M / XDR-TB治疗相比,参与者表示更愿意接受抗逆转录病毒治疗,因为它具有更高的耐受性,较低的药丸负担和对抗逆转录病毒疗法的承诺。与艾滋病毒/艾滋病相比,人们普遍认为与M / XDR-TB相关的治疗结果和社会发病率要差于公众通报,污名和社会隔离。沟通不畅,患者参与度低以及提供者对治疗的监督加剧了参与者对结核病护理的不良经历。为了提高依从性,至关重要的是要开发出具有更高疗效,更低药丸负担和更少不良反应的耐药结核病新疗法。这种改进的治疗方法将首次出现。同时并同等重要的是,实施一种凝聚力的方法,以促进患者对艾滋病毒和结核病的参与,赋权和治疗素养。

著录项

  • 来源
    《Global public health》 |2014年第10期|1107-1116|共10页
  • 作者单位

    Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY 10027 USA|Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, Nelson R Mandela Sch Med, Durban, South Africa;

    Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, Nelson R Mandela Sch Med, Durban, South Africa;

    Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, Nelson R Mandela Sch Med, Durban, South Africa|Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, New York, NY USA|Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    adherence; qualitative methods; drug-resistant tuberculosis; co-infection; HIV/AIDS;

    机译:依从性;定性方法;抗药性结核;合并感染;HIV / AIDS;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号